Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Xisimin (Loratadine) vs Clarityne in Healthy Subjects
NCT03151720Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Xisimin in allergic rhinitis (AR) and urticaria (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Relative Bioavailability of Xisimin Compared With Clarityne. Started Jun 2017; status: completed.
02
Drugs
Xisimin
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT03151720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151720.